BillionToOne, Inc.

# Signal Note: Perceptive Advisors Initiates BLLN Position Edelman's $6M entry into BillionToOne suggests conviction in the company's non-invasive prenatal testing (NIPT) platform and potential expansion beyond current cfDNA screening applications. The position timing may reflect anticipated clinical or commercial catalysts, though near-term catalysts (regulatory decisions, partnership announcements, or expanded reimbursement) should be monitored given Perceptive's track record favoring clinical-stage inflection points.